These include such settings as outpatient clinics, urgent care clinics or emergency rooms in areas that have in the past been deemed low-risk for HIV. The researchers recommended expanded testing because of the success over the past decade of highly active antiretroviral therapy (HAART) in prolonging the quantity and quality of lives of patients infected with AIDS, as well as decreasing the rate at which those infected with the virus can transmit the disease to others.
HAART therapy involves using multiple drugs, all of which block replication of HIV genes. For most patients, these drugs combinations have reduced the viral load in the blood to virtually undetectable levels. Not only has this therapy increased the life expectancies of infected patients, but researchers believe that HAART also reduces their infectivity.
The results of the cost-effectiveness analysis were published Feb. 10, 2005, in the New England Journal of Medicine.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a one percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits. In addition we found this screening would be cost-effective and in-line with other commonly accepted screening programs," said lead author Gillian Sanders, Ph.D., a medical decision analyst at the Duke Clinical Research Institute.